565
Views
4
CrossRef citations to date
0
Altmetric
Editorials

Osteoporosis risk in Type 2 diabetes patients

, , &
Pages 423-425 | Published online: 10 Jan 2014

References

  • Schwartz AV, Vittinghoff E, Bauer DC et al. Association of BMD and FRAX score with risk of fracture in older adults with Type 2 diabetes. JAMA 305(21), 2184–2192 (2011).
  • Giangregorio LM, Leslie WD, Lix LM et al. FRAX underestimates fracture risk in patients with diabetes. J. Bone Miner. Res. 27(2), 301–308 (2012).
  • Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of Type 1 and Type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166(5), 495–505 (2007).
  • Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with Type 1 and Type 2 diabetes – a meta-analysis. Osteoporos. Int. 18(4), 427–444 (2007).
  • Bonds DE, Larson JC, Schwartz AV et al. Risk of fracture in women with Type 2 diabetes: the Women's Health Initiative Observational Study. J. Clin. Endocrinol. Metab. 91(9), 3404–3410 (2006).
  • Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J. Biphasic fracture risk in diabetes: a population-based study. Bone 40(6), 1595–1601 (2007).
  • de LII, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos. Int. 16(12), 1713–1720 (2005).
  • Schwartz AV, Sellmeyer DE, Ensrud KE et al. Older women with diabetes have an increased risk of fracture: a prospective study. J. Clin. Endocrinol. Metab. 86(1), 32–38 (2001).
  • Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in Type 2 diabetes: a meta-analysis. CMAJ 180(1), 32–39 (2009).
  • Schaffler MB, Burr DB. Stiffness of compact bone: effects of porosity and density. J. Biomech. 21(1), 13–16 (1988).
  • Patsch JM, Burghardt AJ, Yap SP et al. Increased cortical porosity in Type 2 diabetic postmenopausal women with fragility fractures. J. Bone Miner. Res. 28(2), 313–324 (2013).
  • Leslie WD, Aubry-Rozier B, Lamy O, Hans D, Manitoba Bone Density P. TBS (Trabecular Bone Score) and diabetes-related fracture risk. J. Clin. Endocrinol. Metab. 98(2), 602–609 (2013).
  • Melton LJ3rd, Riggs BL, Leibson CL et al. A bone structural basis for fracture risk in diabetes. J. Clin. Endocrinol. Metab. 93(12), 4804–4829 (2008).
  • Petit MA, Paudel ML, Taylor BC et al. Bone mass and strength in older men with Type 2 diabetes: The Osteoporotic Fractures in Men Study. J. Bone Miner. Res. 25(2), 285–291 (2010).
  • Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos. Int. 20(6), 887–894 (2009).
  • Schwartz AV, Garnero P, Hillier TA et al. Pentosidine and increased fracture risk in older adults with Type 2 diabetes. J. Clin. Endocrinol. Metab. 94(7), 2380–2386 (2009).
  • Schwartz AV, Margolis KL, Sellmeyer DE et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care 35(7), 1525–1531 (2012).
  • Oei L, Zillikens MC, Dehghan A et al. High bone mineral density and fracture risk in Type 2 diabetes as skeletal complications of inadequate glucose control: the rotterdam study. Diabetes Care 36(6), 1619–1628 (2013).
  • Patsch JM, Li X, Baum T et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J. Bone Miner. Res. 28(8), 1721–1728. (2013).
  • Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 44(7), 775–782 (1995).
  • Manavalan JS, Cremers S, Dempster DW et al. Circulating osteogenic precursor cells in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97(9), 3240–3250 (2012).
  • Dobnig H, Piswanger-Solkner JC, Roth M et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J. Clin. Endocrinol. Metab. 91(9), 3355–3363 (2006).
  • Gaudio A, Privitera F, Battaglia K et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97(10), 3744–3750.
  • Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J. Bone Miner. Res. 27(11), 2231–2237 (2012).
  • Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in Type 2 diabetic women: the fracture intervention trial. Diabetes Care 27(7), 1547–1553 (2004).
  • Vestergaard P, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif. Tissue Int. 88(3), 209–214 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.